Strategic Signals Weekly

Adagio Medical Holdings, Inc. has initiated a process to explore a full range of strategic alternatives to enhance shareholder value, which may include M&A. Concurrently, the company is reducing its workforce by 25 out of 43 full-time employees, effective September 23, 2026, anticipating approximately $1.3 million in cash expenditures for severance and related costs. The company also lowered the conversion price for its 13% Senior Secured Convertible Notes to facilitate potential conversions during this period.

Tessera Defense and Homeland Security Inc., through its subsidiary Tessera Israel, entered into an Option Agreement with X S.E. Security and Defense Ltd. to potentially acquire a 51% stake in RT LTA Systems Ltd., a developer of tethered aerostat systems for surveillance. Tessera Israel paid $1 million for this 90-day option, which is creditable against the purchase price if exercised. The total purchase price for the 51% stake is capped at $13 million, with payments structured upon option exercise and based on RT's future financial performance.

Partner: X S.E. Security and Defense Ltd.

Ionis Pharmaceuticals and its partner Roche announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in proteinuria reduction compared to placebo. The safety profile of sefaxersen was consistent with previously reported data, with no new safety signals identified.

Drug: sefaxersen · Indication: primary IgA nephropathy · Partner: Roche Holding Ltd.

Zymeworks entered into a Contingent Value Rights (CVR) Agreement related to ampreloxetine, entitling CVR holders to a pro rata share of future monetization proceeds. This includes 80% of net proceeds from any license or divestiture, a $50 million milestone upon the first commercial sale in key markets (U.S., UK, Spain, France, Germany, or Italy), and 10% of net sales. This agreement outlines the contingent value distribution for ampreloxetine's future commercial success or out-licensing.

Drug: ampreloxetine

NewAmsterdam Pharma and its partner Menarini Group announced that the European Commission granted marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe FDC) for primary hypercholesterolaemia or mixed dyslipidaemia. This marks the first regulatory approval of obicetrapib worldwide, covering EU Member States, Iceland, Liechtenstein, and Norway. Menarini holds exclusive European commercialization rights, with NewAmsterdam Pharma eligible for tiered double-digit royalties and up to "833 million in milestones, including mid-teen millions triggered by this authorization.

Drug: obicetrapib · Indication: primary hypercholesterolaemia (heterozygous familial (HeFH) and non-familial) or mixed dyslipidaemia · Partner: Menarini Group

Creative Medical Technology Holdings, Inc. acquired an additional 4,000,000 shares of BioDefense, Inc. common stock from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock. This transaction increased Creative Medical Technology Holdings' ownership in BioDefense to 80% of outstanding shares. The Company's shares were issued in a private placement.

HCW Biologics Inc. entered into a Securities Purchase Agreement with an existing institutional investor to sell 903,614 units, each consisting of a pre-funded warrant and the right to receive a common stock purchase warrant, for aggregate gross proceeds of approximately $1.5 million. The company intends to use the net proceeds for working capital and general corporate purposes, including continuing clinical development activities. The issuance of common warrants is subject to stockholder approval.

Glucotrack, Inc. entered into a securities purchase agreement with institutional investors for a registered direct offering of common stock and pre-funded warrants. The offering is expected to generate approximately $3.1 million in gross proceeds, which the company plans to use for debt repayment, working capital, and general corporate purposes. The closing of the offering is anticipated on September 25, 2026.

Decoy Therapeutics Inc. entered into a warrant inducement letter agreement with a holder, resulting in the immediate cash exercise of Series B Milestone Warrants. This transaction generated approximately $3.85 million in gross proceeds for the company, which will be used for working capital and general corporate purposes. In consideration, the company reduced the exercise price of existing warrants and issued new unregistered warrants to the holder.

Aptevo Therapeutics Inc. held a Special Meeting of Stockholders on September 22, 2026. Stockholders approved the issuance of over 20% of the company's common stock for warrant reload and private placement transactions, as well as the Fifth Amended and Restated 2018 Stock Incentive Plan. An amendment to the company's Certificate of Incorporation was not approved.